Last reviewed · How we verify
NCT03909022
Assessing Best Medical Treatment Patterns of Patients With Symptomatic Peripheral Arterial Occlusive Disease in Germany
trial in Peripheral Artery Disease in 60,000 participants. Status unknown.
31 March 2021
Quick facts
| Lead sponsor | Universitätsklinikum Hamburg-Eppendorf |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 60,000 |
| Start date | 1 January 2008 |
| Primary completion | 31 March 2021 |
| Estimated completion | 1 April 2021 |
Conditions studied
- Peripheral Artery Disease — all drugs for Peripheral Artery Disease →
- Intermittent Claudication — all drugs for Intermittent Claudication →
- Critical Limb Ischemia — all drugs for Critical Limb Ischemia →
Sponsor
Universitätsklinikum Hamburg-Eppendorf — full company profile →
Who can join
18 and older, any sex, with Peripheral Artery Disease or Intermittent Claudication. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This proposed study will be conducted to support real-world-evidence on the extent of best medical treatment for secondary prevention of patients with symptomatic peripheral arterial occlusive disease (PAOD) for prevention of worsening limb symptoms or of major adverse cardiovascular events. The overall objective of this study is to gain a better understanding of patient characteristics, treatment patterns and outcomes in PAOD patients. For this purpose the investigators will analyze a patient population hospitalized either with intermittent claudication (IC) or chronic limb-threatening ischaemia (CLTI) while taking prior PAOD-related diagnoses in the outpatient setting into account. In detail, we study differentials according to age, calendar time, sex, disease severity and hospital procedure. Data were extracted from available German health insurance claims.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Editor's Choice - Optimal Pharmacological Treatment of Symptomatic Peripheral Arterial Occlusive Disease and Evidence of Female Patient Disadvantage: An Analysis of Health Insurance Claims Data.
Peters F, Kreutzburg T, Rieß HC, Heidemann F, et al · · 2020 · cited 33× · PMID 32669223 · DOI 10.1016/j.ejvs.2020.05.001 -
Long-Term Effectiveness and Safety of Initiating Statin Therapy After Index Revascularization In Patients With Peripheral Arterial Occlusive Disease.
Peters F, Kuchenbecker J, Kreutzburg T, Marschall U, et al · · 2020 · cited 16× · PMID 33183157 · DOI 10.1161/jaha.120.018338 -
Antithrombotic Treatment Patterns of Patients with Symptomatic Peripheral Arterial Occlusive Disease in Germany: Evidence from Health Insurance Claims Data.
Peters F, Kuchenbecker J, Acar L, Marschall U, et al · · 2022 · cited 5× · PMID 36143102 · DOI 10.3390/jcm11185455 -
A retrospective cohort study on the provision and outcomes of pharmacological therapy after revascularisation for peripheral arterial occlusive disease: a study protocol.
Peters F, Kreutzburg T, Kuchenbecker J, Debus S, et al · · 2020 · cited 5× · PMID 35047784 · DOI 10.1136/bmjsit-2019-000020 -
Data sources and applied methods for paclitaxel safety signal discernment.
Gressler LE, Avila-Tang E, Mao J, Avalos-Pacheco A, et al · · 2023 · cited 1× · PMID 38463423 · DOI 10.3389/fcvm.2023.1331142
Verify or expand the search:
- PubMed search for NCT03909022
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Peripheral Artery Disease
Currently open trials in the same condition.
- NCT07374601 — The Value of Super-resolution Ultrasound Imaging for Peripheral Artery Disease · recruiting
- NCT06686121 — Improving Mobility After Revascularization in Peripheral Artery Disease · Phase 3 · recruiting
- NCT04433572 — Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee · Phase 3 · recruiting
- NCT06890208 — Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave · recruiting
- NCT07012070 — Improving Walking Performance in Patients With Peripheral Artery Disease Through Wearable Activity Trackers · NA · recruiting
Other Universitätsklinikum Hamburg-Eppendorf trials
Trials by the same sponsor.
- NCT07443384 — Complications Associated With Radiofrequency Microneedling in Dermatology: a Delphi Consensus · not yet recruiting
- NCT07385092 — Continuous Vital Sign Monitoring Versus Routine Spot-checks in Patients After Non-cardiac Surgery · NA · recruiting
- NCT07009522 — Hamburg Emotion Awareness and Regulation Group Training for Autistic Adolescents (HEART) · EARLY_PHASE1 · not yet recruiting
- NCT07115394 — EEG Measurements to Capture DBS-induced Electric Potentials · recruiting
- NCT06955884 — Patient Experience of Transoral Versus Transnasal Awake Tracheal Intubation · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03909022 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universitätsklinikum Hamburg-Eppendorf
- Last refreshed: 14 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03909022.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing